Urate oxidase should remain mandatory in patients at high risk of tumor lysis syndrome.

Authors	Michael Darmon, Aurelie Bourmaud, François Vincent
Journal	American journal of kidney diseases : the official journal of the National Kidney Foundation (Am J Kidney Dis) Vol. 63 Issue 1 Pg. 165-6 (Jan 2014) ISSN: 1523-6838 [Electronic] United States
PMID	24360225 (Publication Type: Letter, Comment)
Chemical References	Recombinant Proteins Urate Oxidase
Topics	Humans Recombinant Proteins (therapeutic use) Tumor Lysis Syndrome (drug therapy) Urate Oxidase (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!